Pritti MistryBusiness reporter, BBC News PA Media NHS patients will lose access to new cutting-edge treatments because of skyrocketing costs, the pharmaceutical giant Novartis has claimed amid a row over drug pricing deals. The warning comes after talks over the cost of medicines for the UK between Health Secretary Wes Streeting and pharma firms broke … Read more
India’s largest life insurer Life Insurance Corporation (LIC), two-wheeler major Hero MotoCorp and pharma stocks like Novartis, Zydus Lifesciences and Lupin will be among 25 companies which will be holding their record dates for the purpose of dividend. Check if you own any of these stocks: Monday, July 21 It will be the ex-date and … Read more
Reliance Industries became the first Indian company to reach Rs 20 lakh crore in market capitalisation. The energy-to-telecom conglomerate’s market value stood at Rs 20.04 lakh crore ($238.7 billion) on Wednesday, catapulting it into the list of world’s most valuable corporations. Surpassing behemoths like Pepsico, Novartis, Industrial and Commercial Bank of China, and SAP in … Read more
Hyderabad: Ever since the COVID-19 pandemic, technology has emerged at the forefront of equitable, precise, and effective healthcare delivery, becoming an essential cog in the wheel of India’s healthcare industry. We now live in a world where medical advancements and technological advancements traverse hand in hand, and healthcare can not be imagined without the effective … Read more
BRUSSELS: A World Health Organization-led scheme to supply COVID-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but is shunning Gilead’s remdesivir blockbuster therapy, an internal document shows. The WHO draft document, seen by Reuters and dated Oct. 30, says the priorities are to secure monoclonal antibodies in a tight … Read more
By Naomi Kresge Vaccines alone won’t be enough to fight Covid-19, Novartis AG Chief Executive Officer Vas Narasimhan said. Treatments will also play a crucial role. Significant supplies of highly effective vaccines probably won’t be available until the end of next year, according to Narasimhan, who headed development for Novartis’s former vaccines unit before it … Read more